Spero Therapeutics Announces FDA Acceptance and Priority Review of Tebipenem HBr New Drug Application for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis
Spero Therapeutics, Inc. today announced that the U.S. FDA has granted Priority Review designation and confirmed acceptance for substantive review of the New Drug Application (NDA) seeking approval fo ...
